Sun Pharmaceutical Industries Limited

“Sun Pharma is a high-quality compounder — India's dominant branded generics franchise with a credible US specialty transition underway, net cash balance sheet, and a proven capital allocator in Dilip Shanghvi — but at 32x forward earnings near its 52-week high, the quality premium is fully reflected and base-case annualized returns are only 8-10%, insufficient to compensate for governance opacity and US specialty execution risk. The business deserves ownership at the right price; INR 1,400-1,550 would offer a genuinely compelling entry.”